1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition 21
3.2 Scope of the Study 21
3.3 Research Objective 21
3.4 Assumptions & Limitations 21
3.4.1 Assumptions 21
3.4.2 Limitations 21
3.5 Market Structure 22
4 Research Methodology
4.1 Research Process 24
4.2 Primary Research 25
4.3 Secondary Research 26
4.4 Market Size Estimation 27
4.5 Forecast Model 27
5 Market Dynamics
5.1 Introduction 29
5.2 Drivers 30
5.2.1 Rising prevalence of autoimmune diseases 30
5.2.2 Increasing research and development related to plasma-derived medicines 30
5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 30
5.3 Restraints 31
5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment 31
5.3.2 High cost of the IVIG treatment 31
5.4 Opportunity 31
5.4.1 Advancements in the treatment 31
5.5 Clinical Trials Data 32
6 Market Factor Analysis
6.1 Porter’s Five Forces Model 34
6.1.1 Bargaining Power of Suppliers 34
6.1.2 Bargaining Power of Buyers 34
6.1.3 Threat of New Entrants 35
6.1.4 Threat of Substitutes 35
6.1.5 Intense Rivalry 35
6.2 Supply Chain Analysis 36
6.2.1 R&D and Designing 36
6.2.2 Manufacturing 36
6.2.3 Distribution & Sales 36
6.2.4 Post-Sales Monitoring 36
7 Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
7.1 Introduction 38
7.2 Treatment 41
7.3 Diagnosis 41
8 Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
8.1 Introduction 43
8.2 Intravenous 44
8.3 Oral 44
9 Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
9.1 Introduction 46
9.2 Hospitals 47
9.3 Specialty Neurological Clinics 47
9.4 Research & Academic Laboratories 48
10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region
10.1 Introduction 50
10.2 Americas 52
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.2.1 North America 55
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.2.1.1 U.S. 57
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.2.1.2 Canada 59
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.2.2 South America 61
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3 Europe 64
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.1 Western Europe 67
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.1.1 Germany 70
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.1.2 France 72
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.1.3 U.K 74
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.1.4 Italy 76
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.1.5 Spain 78
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.1.6 Rest of Western Europe 80
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.3.2 Eastern Europe 82
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.4 Asia Pacific 84
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.4.1 China 87
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.4.2 Japan 89
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.4.3 India 91
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.4.4 Australia 93
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.4.5 Republic of Korea 95
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.4.6 Rest of Asia Pacific 97
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.5 Middle East and Africa 99
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.5.1 Middle East 102
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
10.5.2 Africa 104
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
11 Competitive Landscape
11.1 Company Market Share Analysis 107
11.2 Introduction 107
12 Company Profiles
12.1 Grifols 110
12.1.1 Company Overview 110
12.1.2 Financial Overview 110
12.1.3 Products/Services Offered 111
12.1.4 SWOT Analysis 111
12.1.5 Key Developments 111
12.1.6 Key strategy 111
12.2 Shire 112
12.2.1 Company Overview 112
12.2.2 Financial Overview 112
12.2.3 Products/Services Offered 113
12.2.4 SWOT Analysis 113
12.2.5 Key Developments 113
12.2.6 Key strategy 113
12.3 Baxter 114
12.3.1 Company Overview 114
12.3.2 Company Overview 114
12.3.3 Products/Services Offered 115
12.3.4 SWOT Analysis 115
12.3.5 Key Developments 115
12.3.6 Key strategy 115
12.4 Pfizer, Inc. 116
12.4.1 Company Overview 116
12.4.2 Financial Overview 116
12.4.3 Products/Services Offered 117
12.4.4 SWOT Analysis 117
12.4.5 Key Developments 117
12.4.6 Key Strategy 117
12.5 CSL Behring 118
12.5.1 Company Overview 118
12.5.2 Financial Overview 118
12.5.3 Products/Services Offered 119
12.5.4 SWOT Analysis 119
12.5.5 Key Developments 119
12.5.6 Key Strategy 120
12.6 Kedrion S.p.A 121
12.6.1 Company Overview 121
12.6.2 Financial Overview 121
12.6.3 Products/Services Offered 122
12.6.4 SWOT Analysis 122
12.6.5 Key Development 122
12.6.6 Key Strategy 122
12.7 Octapharma 123
12.7.1 Company Overview 123
12.7.2 Financial Overview 123
12.7.3 Products/Services Offered 123
12.7.4 SWOT Analysis 124
12.7.5 Key Development 124
12.7.6 Key Strategy 124
12.8 Momenta Pharmaceuticals 125
12.8.1 Company Overview 125
12.8.2 Financial Overview 125
12.8.3 Products/Services Offered 126
12.8.4 SWOT Analysis 126
12.8.5 Key Development 126
12.8.6 Key Strategy 126
12.9 Teijin Pharma Limited 127
12.9.1 Company Overview 127
12.9.2 Financial Overview 127
12.9.3 Products/Services Offered 128
12.9.4 SWOT Analysis 128
12.9.5 Key Developments 128
12.9.6 Key strategy 128
12.10 Mitsubishi Tanabe Pharma Corporation 129
12.10.1 Company Overview 129
12.10.2 Financial Overview 129
12.10.3 Products/Services Offered 130
12.10.4 SWOT Analysis 130
12.10.5 Key Developments 130
12.11 Bio Products Laboratory Ltd. 131
12.11.1 Company Overview 131
12.11.2 Financial Overview 131
12.11.3 Products/Services Offered 131
12.11.4 SWOT Analysis 131
12.11.5 Key Developments 131
12.11.6 Key strategy 131
13 Appendix
13.1 Discussion Blue Print 133
14 List of Tables
TABLE 1 MARKET SYNOPSIS 19
TABLE 2 PRIMARY INTERVIEWS 24
TABLE 3 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 39
TABLE 4 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 40
TABLE 5 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 40
TABLE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 40
TABLE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY REGION,
2020-2027 (USD MILLION) 41
TABLE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY REGION,
2020-2027 (USD MILLION) 41
TABLE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 44
TABLE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR INTRAVENOUS BY REGION,
2020-2027 (USD MILLION) 44
TABLE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ORAL BY REGION,
2020-2027 (USD MILLION) 44
TABLE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY END USER, 2020-2027 (USD MILLION) 47
TABLE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR HOSPITALS, BY REGION,
2020-2027 (USD MILLION) 47
TABLE 14 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR SPECIALTY NEUROLOGICAL CLINICS,
BY REGION, 2020-2027 (USD MILLION) 47
TABLE 15 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR RESEARCH & ACADEMIC
LABORATORIES, BY REGION, 2020-2027 (USD MILLION) 48
TABLE 16 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 51
TABLE 17 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 52
TABLE 18 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 52
TABLE 19 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 53
TABLE 20 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 53
TABLE 21 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 53
TABLE 22 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 54
TABLE 23 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 54
TABLE 24 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,
2020-2027 (USD MILLION) 55
TABLE 25 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,
BY TREATMENT & DIAGNOSIS, 2020-2027 (USD MILLION) 55
TABLE 26 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT
BY TYPE, 2020-2027 (USD MILLION) 55
TABLE 27 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS
BY TYPE, 2020-2027 (USD MILLION) 56
TABLE 28 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC
TESTING BY TYPE, 2020-2027 (USD MILLION) 56
TABLE 29 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF
ADMINISTRATION, 2020-2027 (USD MILLION) 56
TABLE 30 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 57
TABLE 31 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 57
TABLE 32 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 57
TABLE 33 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 58
TABLE 34 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 58
TABLE 35 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 58
TABLE 36 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 59
TABLE 37 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 59
TABLE 38 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 59
TABLE 39 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 60
TABLE 40 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 60
TABLE 41 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 60
TABLE 42 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 61
TABLE 43 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &
DIAGNOSIS, 2020-2027 (USD MILLION) 61
TABLE 44 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 61
TABLE 45 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 62
TABLE 46 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC
TESTING BY TYPE, 2020-2027 (USD MILLION) 62
TABLE 47 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF
ADMINISTRATION, 2020-2027 (USD MILLION) 62
TABLE 48 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 63
TABLE 49 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 64
TABLE 50 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 64
TABLE 51 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 65
TABLE 52 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 65
TABLE 53 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 65
TABLE 54 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 66
TABLE 55 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 66
TABLE 56 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,
2020-2027 (USD MILLION) 67
TABLE 57 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &
DIAGNOSIS, 2020-2027 (USD MILLION) 67
TABLE 58 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT
BY TYPE, 2020-2027 (USD MILLION) 68
TABLE 59 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS
BY TYPE, 2020-2027 (USD MILLION) 68
TABLE 60 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC
TESTING BY TYPE, 2020-2027 (USD MILLION) 68
TABLE 61 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF
ADMINISTRATION, 2020-2027 (USD MILLION) 69
TABLE 62 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 69
TABLE 63 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 70
TABLE 64 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 70
TABLE 65 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 70
TABLE 66 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 71
TABLE 67 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 71
TABLE 68 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 71
TABLE 69 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 72
TABLE 70 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
\2020-2027 (USD MILLION) 72
TABLE 71 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 72
TABLE 72 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 73
TABLE 73 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 73
TABLE 74 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 73
TABLE 75 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 74
TABLE 76 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 74
TABLE 77 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 74
TABLE 78 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 75
TABLE 79 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 75
TABLE 80 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 75
TABLE 81 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 76
TABLE 82 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 76
TABLE 83 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 76
TABLE 84 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 77
TABLE 85 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 77
TABLE 86 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 77
TABLE 87 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 78
TABLE 88 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 78
TABLE 89 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 78
TABLE 90 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 79
TABLE 91 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 79
TABLE 92 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 79
TABLE 93 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,
BY TREATMENT & DIAGNOSIS, 2020-2027 (USD MILLION) 80
TABLE 94 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR
TREATMENT BY TYPE, 2020-2027 (USD MILLION) 80
TABLE 95 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR
DIAGNOSIS BY TYPE, 2020-2027 (USD MILLION) 80
TABLE 96 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR
ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 81
TABLE 97 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,
BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 81
TABLE 98 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 81
TABLE 99 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &
DIAGNOSIS, 2020-2027 (USD MILLION) 82
TABLE 100 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT
BY TYPE, 2020-2027 (USD MILLION) 82
TABLE 101 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS
BY TYPE, 2020-2027 (USD MILLION) 82
TABLE 102 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC
TESTING BY TYPE, 2020-2027 (USD MILLION) 83
TABLE 103 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF
ADMINISTRATION, 2020-2027 (USD MILLION) 83
TABLE 104 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 83
TABLE 105 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,
2020-2027 (USD MILLION) 84
TABLE 106 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &
DIAGNOSIS, 2020-2027 (USD MILLION) 84
TABLE 107 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 85
TABLE 108 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 85
TABLE 109 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC
TESTING BY TYPE, 2020-2027 (USD MILLION) 85
TABLE 110 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 86
TABLE 111 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 86
TABLE 112 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 87
TABLE 113 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 87
TABLE 114 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 87
TABLE 115 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 88
TABLE 116 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 88
TABLE 117 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 88
TABLE 118 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 89
TABLE 119 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 89
TABLE 120 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 89
TABLE 121 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 90
TABLE 122 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 90
TABLE 123 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 90
TABLE 124 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 91
TABLE 125 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 91
TABLE 126 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 91
TABLE 127 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 92
TABLE 128 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 92
TABLE 129 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 92
TABLE 130 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 93
TABLE 131 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 93
TABLE 132 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 93
TABLE 133 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 94
TABLE 134 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 94
TABLE 135 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 94
TABLE 136 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &
DIAGNOSIS, 2020-2027 (USD MILLION) 95
TABLE 137 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT
BY TYPE, 2020-2027 (USD MILLION) 95
TABLE 138 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 95
TABLE 139 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR
ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 96
TABLE 140 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF
ADMINISTRATION, 2020-2027 (USD MILLION) 96
TABLE 141 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 96
TABLE 142 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &
DIAGNOSIS, 2020-2027 (USD MILLION) 97
TABLE 143 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT
BY TYPE, 2020-2027 (USD MILLION) 97
TABLE 144 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS
BY TYPE, 2020-2027 (USD MILLION) 97
TABLE 145 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR
ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 98
TABLE 146 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF
ADMINISTRATION, 2020-2027 (USD MILLION) 98
TABLE 147 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 98
TABLE 148 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION,
2020-2027 (USD MILLION) 99
TABLE 149 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &
DIAGNOSIS, 2020-2027 (USD MILLION) 99
TABLE 150 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT
BY TYPE, 2020-2027 (USD MILLION) 100
TABLE 151 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS
BY TYPE, 2020-2027 (USD MILLION) 100
TABLE 152 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR
ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 100
TABLE 153 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 101
TABLE 154 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 101
TABLE 155 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 102
TABLE 156 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 102
TABLE 157 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 102
TABLE 158 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC
TESTING BY TYPE, 2020-2027 (USD MILLION) 103
TABLE 159 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 103
TABLE 160 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,
2020-2027 (USD MILLION) 103
TABLE 161 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020-2027 (USD MILLION) 104
TABLE 162 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,
2020-2027 (USD MILLION) 104
TABLE 163 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,
2020-2027 (USD MILLION) 104
TABLE 164 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING
BY TYPE, 2020-2027 (USD MILLION) 105
TABLE 165 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020-2027 (USD MILLION) 105
TABLE 166 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 105
15 List of Figures
FIGURE 1 RESEARCH PROCESS 24
FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH 27
FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
(CIDP) MARKET 29
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 34
FIGURE 5 SUPPLY CHAIN: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 36
FIGURE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY TREATMENT & DIAGNOSIS,
2020 (%) 39
FIGURE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,
2020 & 2027 (USD MILLION) 39
FIGURE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY ROUTE OF
ADMINISTRATION, 2020 (%) 43
FIGURE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,
2020 & 2027 (USD MILLION) 43
FIGURE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY END USER, 2020 (%) 46
FIGURE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USER, 2020 & 2027 (USD MILLION) 46
FIGURE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 50
FIGURE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 51
FIGURE 14 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 52
FIGURE 15 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 64
FIGURE 16 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2020 (%) 67
FIGURE 17 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2020 (%) 84
FIGURE 18 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE,
BY COUNTRY, 2020 (%) 99
FIGURE 19 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET SHARE ANALYSIS 2020 (%) 107
